Muc1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same

Abstract

The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.

1 . A peptide comprising eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12, and consisting of eleven or less amino acid residues. 
     
     
         2 . The peptide according to  claim 1 , wherein one or several amino acids in the amino acid sequence are substituted, inserted, deleted, or added, and the peptide has immunogenicity. 
     
     
         3 . The peptide according to  claim 2 , wherein an amino acid at a 2-position of the amino acid sequence is substituted with tyrosine, phenylalanine, methionine, tryptophan, valine, leucine or glutamine, and/or a C-terminal amino acid is substituted with phenylalanine, leucine, isoleucine, tryptophan, methionine, or valine. 
     
     
         4 . A pharmaceutical composition for treatment or prevention of cancer, comprising the peptide according to  claim 1 . 
     
     
         5 . The pharmaceutical composition according to  claim 4 , which is in a form of vaccine. 
     
     
         6 . The pharmaceutical composition according to  claim 4 , wherein the peptide can bind to one or more types of HLA molecules. 
     
     
         7 . An immunity-inducing agent comprising the peptide according to  claim 1 . 
     
     
         8 . The immunity-inducing agent according to  claim 7 , which is used to induce a cytotoxic T cell. 
     
     
         9 . The immunity-inducing agent according to  claim 7 , wherein the peptide can bind to one or more types of HLA molecules. 
     
     
         10 . A method for manufacturing an antigen presenting cell having a CTL-inducing activity, the method comprising a step of bringing the peptide according to  claim 1  into contact with an antigen presenting cell in vitro.